• J A Corless and C J Warburton.
• Aintree Chest Centre, University Hospital, Aintree, Aintree Chest Centre, University Hospital Aintree, Lower Lane, Liverpool, Merseyside, UK, L9 7AL. j.corless@bigfoot.com
• Cochrane Db Syst Rev. 2000 Jan 1 (4): CD002174.

BackgroundLeukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis.ObjectivesTo determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage).Search StrategyThe Cochrane Airways Group clinical trials register derived from MEDLINE, EMBASE and hand searching of major journals was searched using the terms:Bronchiec* AND leukotrien* OR anti-leuk* OR cysteinyl, Bronchiec* AND monteluk*, Bronchiec* AND zafirluk*Selection CriteriaOnly randomised, controlled trials were consideredData Collection And AnalysisThe results of searches were analysed by both authorsMain ResultsNo randomised, controlled trials were identifiedReviewer's ConclusionsFurther research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis.

14 keywords...

hide…